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A B S T R A C T
Introduction: Metastatic bone disease (MBD) carries signiﬁcant morbidity for patients with cancer. MBD from
malignant melanoma (MM) is understudied. We examined the characteristics, morbidity, management and
outcome of MBD in patients with MM.
Methods: Patients with metastatic MM managed at two referral cancer centres in England were identiﬁed. Those
with bone metastases (BMs) were selected. Patient and disease characteristics including skeletal related events
(SREs) were extracted from medical records. The Kaplan Meier method was used to calculate median survival.
Results: Five hundred and eighteen patients with metastatic MM were managed between years 2000 and 2008.
Eighty nine (17.2%) patients had BMs and are the subject of this study. Median age at diagnosis was 53 years and
55% were males. BMs were identiﬁed at the time of diagnosis of metastatic disease in 68.5% patients. Sixty-six
(74.2%) had multiple bone lesions and 80.9% had axial skeleton involvement. One hundred and twenty nine
skeletal related events occurred in 59 (66.3%) patients (50 radiotherapy, 28 hypercalcaemia, 20 bone fractures,
18 spinal cord compression and 13 orthopaedic surgery). The annual skeletal morbidity rate was 2.5.
Median survival from diagnosis of BMs was 17.3 weeks and was 5.6 weeks from the ﬁrst episode of hy-
percalcaemia.
Conclusion: MBD aﬀects a clinically important proportion (17.2%) of patients with metastatic MM. It carries a
substantial morbidity and mortality exceeding that caused by BMs from breast and prostate cancer. These pa-
tients should receive the currently licensed bone modifying agents and should be included in clinical trials
addressing MBD.
1. Introduction
The incidence of malignant melanoma (MM) is increasing world-
wide [1]. Recently developed biological therapies have improved sur-
vival of patients with advanced and metastatic disease. However, the
prognosis for these patients remains poor with median overall survival
shorter than 1.5 years [2]. Melanoma patients with soft tissue (in-
cluding skin and lymph nodes) or lung metastases and normal lactate
dehydrogenase fare better than those with metastases elsewhere (e.g.
liver, brain) and/or raised LDH [3].
Bone is a frequent site for metastases in patients with some of the
common malignancies including breast, prostate and lung cancer.
However, bone metastases (BMs) are more common than often realized
in a range of other malignancies [4]. BMs can cause substantial mor-
bidity and skeletal complications, referred to as skeletal related events
(SREs) including pathological fractures of bones, spinal cord compres-
sion, hypercalcaemia, radiotherapy and surgery to bone (as treatment
for BMs). It is estimated that across all tumour types, one of these major
skeletal events occurs on average every 3–6 months [5].
A large series from Duke University Medical Centre reported BMs in
6.9% of 1677 patients diagnosed with all stages MM between the years
1956 and 1976 [6]. Mean survival from the diagnosis of bone metas-
tases of was 3.6 months suggesting that clinically overt BM from mel-
anoma become apparent towards the end of the disease's trajectory
when rigorous investigation and aggressive interventions may be con-
sidered unjustiﬁed [6].
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MBD from MM remains an under-investigated subject. More recent
series have concentrated on special cases such as isolated skeletal me-
tastases and speciﬁc anatomical bone site metastases [7,8]. In addition,
with the recent improvement in diagnostic and therapeutic landscape
including bone modifying agents, metastatic bone disease (MBD) is
gaining more attention. We therefore conducted a retrospective study
to examine the characteristics, morbidity, management and outcome of
MBD in patients with MM managed in Yorkshire, UK.
2. Methods
2.1. Patient selection and extraction of data
The study was conducted at two regional referral oncology centres
in West and South Yorkshire, UK, namely St. James's University
Hospital, Leeds and Weston Park Hospital, Sheﬃeld.
The study period was January 2000 - March 2008 for the Leeds
centre and January 2000 – December 2005 for the Sheﬃeld centre.
Records of all patients registered with diagnosis of any stage MM in
these periods were screened (Leeds: 1716 and Sheﬃeld: un-
documented) and those with metastatic disease (n = 518) were iden-
tiﬁed. Of these, patients with BMs were selected and are the subject of
this study. Paper and electronic records of these patients were reviewed
in detail. Patients’ and disease characteristics were extracted.
2.2. Clinical classiﬁcations
The distribution of BMs was classiﬁed as axial (skull, thoracic cage
and vertebral column) or appendicular (shoulder girdle, pelvic girdle
and limb bones). Radiology imaging reports were carefully reviewed to
establish and conﬁrm the diagnosis and distribution of bone metastases.
Review of imaging ﬁlms (when available) was performed to clarify
imaging reports only if indicated. SREs were identiﬁed. Hypercalcaemia
was deﬁned as adjusted serum calcium>2.60 mmol/l. After treatment
of hypercalaemia, a recurring event was diagnosed if serum calcium
rises again above 2.60 mmol/l or if it rises above any post-treatment
above normal value. Pathological fractures of bones, spinal cord com-
pression and surgery to bone (as treatment for BMs) were counted on
anatomic basis. For example, 2 synchronous or metachronous bone
fracture or surgeries to bones were counted as 2 separate SREs even if
they involved one bone. Radiotherapy in 2 diﬀerent ﬁelds to 2 diﬀerent
bone sites were counted as 2 separate SREs even if radiotherapy was
delivered during the same period. Treatment of SREs was also recorded.
2.3. Statistical analysis
Duration of follow-up was deﬁned as the time from diagnosis of
melanoma until date of death or date patient was last seen alive. The
Kaplan-Meier method was used to plot the survival distributions and
estimate the median survival times for the time from diagnosis of
melanoma, diagnosis of BMs, and ﬁrst episode of hypercalcaemia to
death. Patients who were still alive at the time of the audit, were
censored at the date they were last known to be alive. The skeletal
morbidity rate (SMR) was deﬁned as to the number of SREs reported,
divided by the person-years at risk i.e. time from diagnosis of BMs to
death / last seen alive.
All analyses were carried out in SAS version 9.4.
3. Results
Medical records of 518 patients with metastatic MM were reviewed
(409 in Leeds and 109 in Sheﬃeld). Eighty nine patients (17.2%) with
BM (70 in Leeds and 19 in Sheﬃeld) were identiﬁed. The median
follow-up time of these 89 patients from initial diagnosis of MM was 2.2
years (range: 0.1–22.7).
Table 1 presents the patient and disease characteristics. The median
age at ﬁrst diagnosis of MM was 53 years (range: 22–93) and 49
(55.1%) were males. For the majority of patients, the primary site of
disease was cutaneous (n = 67, 75.3%).
Six patients (6.7%) presented with BMs at diagnosis of the primary
disease, whilst the remainder developed BM after their initial mela-
noma diagnosis with a median time of 1.8 (range: 0–19.6) years.
BMs were identiﬁed at the time of initial diagnosis of metastatic
disease in 61 (68.5%) patients and later (median 2 months) in the re-
maining 28 (31.5%). Sixty-six patients (74.2%) had BM at multiple
sites.
Fifty-nine patients (66.3%) experienced one or more SRE with over
50% of patients requiring radiotherapy (Table 1). In total 129 SREs
were reported as follows: need for radiotherapy (n = 50), hy-
percalcaemia (n = 28), bone fractures (n = 20), spinal cord com-
pression (n = 18) and orthopaedic surgery (n = 13), representing
38.8%, 21.7%, 15.5%, 14% and 10% of all reported events respectively
(Fig. 1).
Twenty patients (22.5%) developed 28 episodes of hypercalcaemia,
of which 11 patients (55%) received therapeutic bisphosphonates. The
remaining patients received other therapies, had mild chemical
asymptomatic hypercalcaemia or were too unwell for speciﬁc treat-
ment. An additional 16 patients (17.9%) received bisphosphonates
primarily for the management of bone pain.
The annual skeletal morbidity rate was 2.5 (95% CI: 2.1, 2.9) i.e. 2.5
SREs are reported per patient for every year of follow-up.
Four patients were still alive at the time of data collection were
censored in the analyses. The median survival of all patients from the
diagnosis of BMs was 17.3 weeks (95% CI: 11.3–20.4), with a prob-
ability of survival at one year of 8% (Fig. 2). Median survival was 5.6
weeks after the ﬁrst episode of hypercalcaemia (95% CI: 3.0–12.7).
4. Discussion
We reviewed patients with BMs from MM registered at two tertiary
Table 1
Characteristics of malignant melanoma patients with bone metastases (n = 89).
Gender
Males 49 (55.1%)
Females 40 (45.9%)
Age at primary diagnosis of MM
Median (range) 53 (22–93) years
Primary site of MM
Cutaneous 67 (75.3%)
Mucosal or unidentiﬁed 12 (13.5%)
Ocular 8 (9.0%)
Acral 2 (2.2%)
Bone metastases present at diagnosis of primary
disease
Yes 6 (6.7%)
No 83 (93.3%)
Bone metastases present at diagnosis of metastatic
disease
Yes 61 (68.5%)
No 28 (31.5%)
Time between primary diagnosis of MM and bone
metastases Median (range)
1.8 (0.0 – 19.6)
years
Frequency of bone metastases
Single 23 (25.8%)
Multiple 66 (74.2%)
Sites of bone metastases
Only axial 47 (52.8%)
Only appendicular 17 (19.1%)
Axial and appendicular 25 (28.1%)
Patients experiencing SREs 59/89 (66.3%)
Radiotherapy 45 (50.6%)
Hypercalcaemia 20 (22.5%)
Bone fracture 17 (19.1%)
Spinal cord compress 18 (20.2%)
Surgery to bones 12 (13.5%)
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referral cancer centres in Yorkshire. The ﬁndings of this study are in-
tended to shed light on the behaviour and outcome of BMs from MM in
the era when cytotoxic chemotherapy and biological therapies (mostly
interferon) were the standards of care.
The crosstalk between bone, tumour cells, and immune cells is well-
studied. However, radiological response to systemic anti-cancer therapy
in BMs is less frequently observed than that in soft tissue. This could at
least partly due to immune escape by disseminated tumour cells in the
BMs micro-environment [9]. Our ﬁndings will serve as background for
future studies in the current era of targeted therapies, immunotherapy
and checkpoint inhibitors.
The total number of screened cases with all stage MM was not
documented in the Sheﬃeld cohort and was 1716 in the larger Leeds
cohort. The frequency of BMs in patients with all stages in the Leeds
cohort was 4.1% (70/1716). This is in line with 6.9% (116/1677) in
patients diagnosed with MM at Duke University Medical Centre be-
tween the years 1956 and 1976 [6].
This frequency reﬂects the culture where investigations for BMs are
performed only in patients with suspicious symptoms. In addition,
isotope bone scans are recognized to yield false-negative results in 15%
of cases [8]. The true frequency may be higher than reported here.
Indeed, in one study on autopsy, 48.6% of patients with metastatic MM
were found to have BMs [10].
The aim of our study was to investigate BMs in patients with me-
tastatic MM. We found that BMs were diagnosed in 17.2% of patients
with this stage of disease. In accordance with guidelines for the pro-
cedures of referral to site-speciﬁc multi-disciplinary teams, we expect
that the vast majority of patients with metastatic MM in the patient
population studied were referred to one of these two cancer centres
suggesting this ﬁgure is robust [11]. Similarly, another retrospective
review of CT scans in 98 patients with metastatic MM reported BMs in
17 (17.3%) [12].
Around two thirds of patients in our study had BMs at the initial
time they were diagnosed with metastatic MM. This ﬁnding suggests
that patients diagnosed with metastatic disease at any site should be
fully staged as there is a high chance of coexistence of other distant
metastases.
Generally, ocular and mucosal melanomas represent 3.7% and 1.4%
of all primary melanomas respectively [13]. In our series 9% and 13%
of patients with BMs had ocular and mucosal primaries respectively.
This observation suggests that ocular and mucosal melanomas have
higher propensity than cutaneous melanoma to metastasize to bones.
However, this conclusion may be limited by the lack of detailed in-
formation of the all stages screened population.
Majority of patients (80.9%) developed BMs in the axial skeleton
(52.8% axial alone and 28.1% axial and appendicular). Predominance
of BMs from melanoma to the axial skeleton has been previously re-
ported in 80% of 50 patients with BMs from MM [14].
Our results conﬁrm the dismal natural history of these patients with
median survival of 17.3 weeks from the diagnosis of BMs and one year
survival of 8% (Fig. 2). There is a paucity of survival outcome data for
these patients in the literature. In a retrospective review of 428 patients
with recurrent melanoma, patients with metastases in the liver, CNS,
bone and multiple-sites distant disease had shorter survival compared
to those with distant skin, distant lymph node, or pulmonary metastases
as ﬁrst metastatic sites. The median survival of patients with bones as
ﬁrst site of metastasis was 2.4 months (10.4 weeks) and the one year
survival was 10% (data extracted from reported survival curves) [15]. A
mean survival time of 4.7 months was reported for 30 patients diag-
nosed with BMs from MM 25–35 years ago in Los Angeles [14].
Care of patients with high risk and advanced MM in West and South
Yorkshire is centralized in 2 tertiary care referral centres in Leeds and
Sheﬃeld respectively. Consequently, the vast majority of SREs would
have been captured in patients’ records at one of these 2 centres.
Fifty nine (66.3%) of our patients experienced one or more SREs. In
comparison, SREs are reported in 52–64% (no bisphosphonates) and
31–51% (on bisphosphonates) of patients with BMs from breast cancer
[16,17]. This indicates that BMs from MM carry similar or even higher
morbidity than that from breast cancer considering the shorter survival
of patients with metastatic MM. In addition, SREs are well recognized to
have a detrimental eﬀect on physical, emotional and functional well-
being [18].
Hypercalcaemia was the commonest metabolic complication seen in
patients with advanced cancer prior to the era of widespread use of
bisphosphonates for MBD.
Hypercalcaemia is diagnosed in 1.1% of all stage MM. It is asso-
ciated with multiple bone and visceral metastases in the majority of
patients [19,20].
Hypercalcaemia was reported in 56/1146 (4.9%) patients with
metastatic melanoma treated at the American National Cancer Institute
between years 1988 and 2000 [21].
There was no speciﬁc frequency of clinical follow up. Generally, all
patients with metastatic MM attending the study centres were under
regular clinical follow up at variable intervals guided by clinical need.
Biochemical tests including serum calcium measurement were routinely
performed every few weeks (mostly every 3 weeks) for patients on
systemic therapy and less frequently (mostly every 6–8 weeks) for those
who were not.
Our results show that hypercalcaemia is a frequent complication
developing in 22.5% of patients with BMs from MM. This is higher than
its frequency in patients with BMs from breast cancer (8.8–13%; no
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Fig. 1. Distribution of 129 reported skeletal related events.
Fig. 2. Overall survival in weeks from diagnosis of bone metastases.
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bisphosphonates) and (2.6–6%; on bisphosphonates) [16,17].
We conﬁrmed the poor outcome of patients with hypercalcemia and
MBD from MM with median survival of less than 6 weeks. This is in line
with the median survival of 30 days reported earlier [20]. It is clear that
MBD and hypercalcaemia in these patients carry a dismal survival
outcome despite brief correction of calcium level after treatment with
hydration and bisphosphonate [20].
There is recognized association between SREs (e.g. pathological
bone fractures) and increased risk of death in patients with other solid
tumors [22]. It is reasonable to suggest that survival may be improved if
this terminal event (hypercalcaemia) and other SREs are delayed or
prevented. Bisphosphonates, in particular Zoledronic acid (ZA) delay
the development of SREs [4]. In a randomised phase III trial, 773 pa-
tients with BMs from solid tumors (other than breast and prostate; in-
cluding 15 patients with melanoma) were randomized to receive ZA or
placebo. Fewer patients treated with ZA developed SREs at 21 months.
Furthermore ZA signiﬁcantly delayed the median time to ﬁrst SRE (236
vs. 155 days; P = 0.009) [23].
Denosumab is a human monoclonal antibody against receptor ac-
tivator of nuclear factor κB ligand (RANKL). It is licensed for the pre-
vention of SREs in adult patients with BMs from solid tumors. Among
patients with solid tumors other than breast and prostate, denosumab
delayed the time to the ﬁrst on-study SRE more eﬀectively than ZA
[24].
Based on the eﬃcacy of these bone modifying agents, we re-
commend the early use of denosumab or ZA in patients with BMs from
melanoma before the development of SREs. This approach may improve
quality of life by delaying and reducing the occurrence of SREs. At the
same it may improve survival by delaying the pre-terminal event of
“hypercalcaemia”. Actively pursuing the detection of BMs as soon as
recurrent or metastatic disease is diagnosed will facilitate earlier ad-
ministration of bone modifying agents and may enhance their potential
beneﬁts.
Eleven of our patients received bisphosphonates for hypercalcaemia
while others received them for other complications of MBD (e.g. pain).
Due to the retrospective nature of this study, we were unable to as-
certain the exact indications and eﬃcacy in some of these patients. In
addition, many of these patients had poor survival and were often
discharged to hospices or community palliative care teams precluding
detailed follow up.
There is an increasing body of evidence suggesting that bispho-
sphonates exhibit anti-tumour properties [25]. Results of two large
clinical trials and a recent meta-analysis support this notion in post-
menopausal (natural or medically induced menopause) women with
breast cancer [26–28].
There is in vitro and in vivo evidence that ZA induces death of
melanoma cells [29]. Certainly, there are no strong clinical data to
support this notion in the clinical setting. However, colleagues from
London (UK) reported a case of metastatic MM treated with ZA (without
systemic anti-cancer therapy) and achieved complete clinical and
radiological response at all metastatic site (bones and lungs). This re-
sponse lasted for 23 months. Peripheral blood mononuclear cells studies
in this patient suggested that ZA mediated activation of Vγ9Vδ2
gamma-delta T cells to be a possible explanation [30].
RANKL may play an important role in development of BMs from
MM. In vitro studies show that melanoma tumour associated macro-
phages diﬀerentiate into osteoclasts in the presence of RANKL [31]. Cas
Interacting Zinc Finger Protein/ Nuclear Matrix Protein4 (CIZ/NMP4) is
a transcription factor that plays a role in gene regulation in bones
leading to suppression of osteoid synthesis [32]. CIZ/NMP4 expression
is enhanced after RANKL treatment promoting migration of B16 mel-
anoma cell [33]. Recently, denosumab was reported to improve relapse
free survival when compared with placebo in an updated analysis of the
ABCSG-18 trial indicating a probable anti-tumour eﬀect [34]. Pre-
clinical model of experimental metastases and anecdotal clinical ob-
servations demonstrated that anti-CTLA-4 and anti-RANKL antibodies
have modest anti-melanoma activities individually. However, this eﬀect
is considerably enhanced when combined together [35].
Therefore, bisphosphonates and anti-RANKL antibodies may be able
to delay or inhibit the development of BMs from MM. This concept can
be taken as a rationale to investigate these agents in patients with MM
prior to development of BMs.
New agents targeting BMs have been developed. Radium-223
dichloride, a ﬁrst-in-class alpha emitter improves survival of patients
with castration-resistant prostate cancer and BMs and is currently been
investigated in breast cancer and other solid tumors [36,37].
The recent developments in BRAF and MEK targeted therapy (ve-
murafenib, dabrafenib, and trametinib) and checkpoint inhibitor im-
munotherapy (ipilimumab, pembrolizumab, and nivolumab) for meta-
static MM have led to modest but encouraging improvement in outcome
[38]. Such longer survival may well be associated with increased risk of
BMs and SREs and therefore greater need for bone speciﬁc treatments.
In addition, there is evidence that earlier (adjuvant) use of ipilimumab
improves recurrence free survival for patients with completely resected
high risk stage III melanoma [39]. However, the eﬀects of these
therapies on the development, progression and complications of MBD is
not deﬁned. Studying the eﬀects of new therapies on MBD is en-
couraged of which the results can be compared against our ﬁndings
which represent an earlier therapeutic era.
5. Conclusions
Our ﬁndings show that BMs occurs in 4.1% of patients with all
stages MM and in 17.2% of patients with metastatic disease. Two thirds
of patients with BMs experience one or more SRE indicating a sig-
niﬁcant morbidity burden. Generally, these patients have a dismal
survival and hypercalcaemia in particular is a terminal event. Early use
of available bone modifying agents should be considered for these pa-
tients with the opportunity to be included in future studies investigating
novel agents targeting BMs.
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